Now showing items 1-10 of 55
Evaluation of amonafide in disseminated malignant melanoma
(Kluwer Academic Publishers; Springer Science+Business Media, 1993-06)
Amonafide (AMF), NSC 308847 is an investigational anticancer drug acting as a DNA intercalating agent. This paper presents results of a phase II clinical study of AMF in disseminated malignant melanoma. Twenty patients, ...
Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells
(Springer-Verlag; Springer-Verlag Berlin Heidelberg, 1998-09)
Purpose : We have reported previously that the expression of E. coli dUTPase (dutE) can protect HT29 cells from 5-fluorodeoxyuridine (FdUrd)-induced DNA fragmentation and cytotoxicity. In the study reported here, we further ...
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity
(Springer-Verlag, 1987-02)
We compared the acute tubular nephrotoxicity of three platinum compounds in children and adults with solid tumors by monitoring the urinary excretion of alanine aminopeptidase, N -acetyl-β-D-glucosaminidase, and total ...
An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs
(Springer-Verlag, 1993-11)
Aclarubicin is an anthracycline antibiotic that differs from doxorubicin in its structure, mechanism of action, and preclinical toxicity profile, especially its reduced cardiotoxicity. We therefore conducted a side-by-side ...
Augmentation of hepatic doxorubicin extraction with extracorporeal filtration avoids the dose-dependent, nonlinear increase in AUC observed with systemic administration
(Springer-Verlag; Springer-Verlag Berlin Heidelberg, 1997-12)
Purpose : Regional therapy of primary or metastatic liver cancer with low hepatic extraction ratio drugs such as doxorubicin is constrained by development of systemic toxicity. To examine the effect of augmentation of ...
Phase II trial of N-methylformamide in advanced head and neck cancer
(Kluwer Academic Publishers; Martinus Nijhoff Publishers ; Springer Science+Business Media, 1987-06)
Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M 2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior ...
Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes
(Springer-Verlag, 2005-11)
Prostate cancer remains a significant health concern for men in the USA as it is a leading cancer diagnosis and a cause of death. With the use of prostate-specific antigen or screening, a stage migration has occurred with ...
High-dose cisplatin in advanced head and neck cancer
(Springer-Verlag, 1987-04)
In 22 patients with advanced squamous cell carcinoma of the head and neck we evaluated the efficacy and toxicity of 200 mg/m 2 cisplatin administered in 3% NaCl with vigorous hydration. Six patients had previously untreated ...
Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study
(Kluwer Academic Publishers; Springer Science+Business Media, 1990-02)
Fifty-two patients with progressive resistant multiple myeloma were entered in this Southwest Oncology Group Phase II study, using weekly intravenous Aclacinomycin A. Of forty-three evaluable patients for response, there ...
Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study
(Kluwer Academic Publishers; Springer Science+Business Media, 2001-08)
Malignant melanoma is increasing infrequency at a rapid rate in the UnitedStates. Metastatic disease ischemoresistant with DTIC considered themost active single agent. CI-980 is asynthetic mitotic inhibitor that blocks ...